Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
DIANEAL PD-2 with 4.25% dextrose is a peritoneal dialysis solution that creates an osmotic gradient across the peritoneal membrane, promoting diffusion and convection of solutes and ultrafiltration of fluid from the blood into the peritoneal cavity. Dextrose is absorbed systemically and metabolized, providing caloric load.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration: 2 to 2.5 L per exchange, 4 exchanges per day (continuous ambulatory peritoneal dialysis) or as prescribed for automated peritoneal dialysis. Dextrose 4.25% used for ultrafiltration. Dose adjusted based on patient's peritoneal membrane transport characteristics and fluid status.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable as glucose is continuously absorbed; systemic half-life of absorbed dextrose ~1-2 hours
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Renal, peritoneal; ~80% removed via peritoneal dialysis, remainder metabolized to CO2 and water
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution